Hepatocellular carcinoma and patient assessment

Advances in Predictive, Preventive and Personalised Medicine

Volumn 8, Issue , 2015, Pages 21-32

  Mohanty, Smruti ^a,b   Verma, Sid ^a   Dosik, David ^a,b   Hazin, Hesham ^a   Berliner, Leonard ^a,b  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; Chronic alcoholism; Cirrhosis; Diagnosis; Genomics; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Imaging; Pathology; Personalized medicine; Risk factors; Screening; Staging

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; DECARBOXYPROTHROMBIN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHOTRANSFERASE INHIBITOR; PROTHROMBIN; SORAFENIB;

ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER SCREENING; CANCER STAGING; CHEMOEMBOLIZATION; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC INFLAMMATION; CLONORCHIS SINENSIS; COMPUTER ASSISTED TOMOGRAPHY; FASCIOLIASIS; HEPATIC PROGENITOR CELL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPISTHORCHIS VIVERRINI; OXIDATIVE STRESS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCLEROSING CHOLANGITIS; SENSITIVITY AND SPECIFICITY; SURVIVAL;

EID: 84992148105     PISSN: 22113495     EISSN: 22113509     Source Type: Book Series    
DOI: None     Document Type: Article

References (44)

1. Aronsohn A, Mohanty SR (2010) Current treatment strategies for hepatocellular carcinoma. Curr Cancer Ther Rev 6:199–206 2.
2. Abrams P, Marsh JW (2010) Current approach to hepatocellular carcinoma. Surg Clin N Am 90:803–816 3.
3. Roskams T (2011) Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis 15:245–259 4.
4. Tsai W-L, Chung RT (2010) Viral hepatocarcinogenesis. Oncogene 29:2309–2324 5.
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538 6.
6. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576 7.
7. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75:347–354 8.
8. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A et al (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155:323–331 9.
9. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM et al (2009) National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 49(5 Suppl):4–12 10.
10. Tai AW, Chung RT (2009) Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 50:412–420 11.
11. Caldwell S, Park SH (2009) The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 44(Suppl XIX):96–101 12.
12. Fattovich G (2003) Natural history and prognosis of hepatitis B. Sem Liver Diseas 23:47–58 13.
13. Wong LL, Limm WM, Severino R et al (2000) Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6:320–325 14.
14. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422 15.
15. Bolondi L, Sofia S, Siringo S et al (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48:251–259 16.
16. El-Serag HB, Marrero JA, Rudolph L et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763 17.
17. Ishiguchi T, Shimamoto K, Fukatsu H et al (1996) Radiologic diagnosis of hepatocellular carcinoma. Semin Surg Oncol 12:164–169 18.
18. European Association for the Study of the Liver. European Organisation for Research and Treatment of Cancer (2012) EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943 19.
19. Wu JT (1990) Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review. Ann Clin Lab Sci 20:98–105 20.
20. Di Bisceglie AM, Sterling RK, Chung RT et al (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43:434–441 21.
21. Collier J, Sherman M (1998) Screening for hepatocellular carcinoma. Hepatology 27:273–278 22.
22. Chen DS, Sung JL, Sheu JC et al (1984) Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 86:1404–1409 23.
23. Durazo FA, Blatt LM, Corey WG et al (2008) Des-gammacarboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23:1541–1548 24.
24. Sherman M (2001) Alphafetoprotein: an obituary. J Hepatol 34:603–605 25.
25. Sherman M, Bruix J (2011) AASLD practice guideline. Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022 26.
26. Sherman M, Bruix J (2010) AASLD practice guideline. Management of hepatocellular carcinoma. Hepatology Supplement:1–32 27.
27. Marrero JA, Su GL, Wei W et al (2003) Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37:1114–1121 28.
28. Ono M, Ohta H, Ohhira M et al (1990) Measurement of immunoreactive prothrombin, desgamma- carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma. Am J Gastroenterol 85:1149–1154 29.
29. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M et al (2001) Des-gammacarboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91:561–569 30.
30. Torzilli G, Minagawa M, Takayama T et al (1999) Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30:889–893 31.
31. Hayashi PH, Trotter JF, Forman L et al (2004) Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl 10:42–48 32.
32. Wiesner RH, Freeman RB, Mulligan DC (2004) Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 127:261–267 33.
33. Compagnon P, Grandadam S, Lorho R et al (2008) Liver transplantation for hepatocellular carcinoma without preoperative tumor biopsy. Transplantation 86:1068–1076 34.
34. Cance WG, Stewart AK, Menck HR (2000) The national cancer data base report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996.Cancer 88:912–920 35.
35. Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918–928 36.
36. The Cancer of the Liver Italian Program (CLIP) Investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840–845 37.
37. The Cancer of the Liver Italian Program (CLIP) investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751–755 38.
38. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338 39.
39. Fleming ID (2001) AJCC/TNM cancer staging, present and future. J Surg Oncol 77:233–236 40.
40. Vauthey JN, Lauwers GY, Esnaola NF et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536 41.
41. Vauthey JN, Ribero D, Abdalla EK et al (2007) Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204:1016–1028 42.
42. Farinati F, Rinaldi M, Gianni S et al (2000) How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 89:2266–2273 43.
43. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390 44.
44. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655